



2025 Corporate Responsibility Summary

We are working to change lives by changing the course of blood cancer.

May 26, 2026



Overview

Responsible Business & Corporate Citizenship Strategy at Geron

Geron's mission is to change lives by changing the course of blood cancer. Our dedicated team leverages the pioneering science of telomerase inhibition with the goal of developing and delivering new therapies for people with hematologic malignancies.

We endeavor to make a meaningful, positive impact through supporting people with blood cancer; fostering a strong, engaged workforce; and governing with integrity and impact.

We look forward to all that is ahead for Geron and the treatment of patients with blood cancers.

Oversight

The Nominating and Corporate Governance Committee oversees our responsible business and good corporate citizenship efforts. Our entire Board oversees our corporate governance, risk management, and key business strategies, as described on Page 12 in this report. The Board is updated periodically about corporate responsibility related activities.

Our responsible business initiatives are driven by a cross-functional working group of employees and members of management from across the organization, including corporate communications, finance, human resources, legal, investor relations, and commercial.

Pillars



Healthier People

Serving Blood Cancer Patients and Those Who Care for Them



Human Capital

Fostering and Maintaining a Strong, Healthy Culture



Governance

Governing with Integrity and Impact

Healthier People

Supporting People with Blood Cancer and Those Who Care for Them

We are passionate about improving treatment options for patients with blood cancer. Our science, expertise and commitment to transforming the blood cancer treatment landscape drives our urgency to deliver innovative therapies to patients and support healthcare practitioners (HCPs) and care partners.



RYTELO™ (imeteLstat) is the first and only telomerase inhibitor approved in the U.S. and Europe. RYTELO received U.S. Food and Drug Administration (FDA) approval in June 2024 for the treatment of adult patients with low to intermediate –1 risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for MDS include imeteLstat (RYTELO) for the treatment of symptomatic anemia in patients with lower-risk MDS, recommending imeteLstat (RYTELO) in second line therapy as a NCCN Category 1 treatment option for RS+ and RS- ESA-eligible patients and in first line therapy as a 2A treatment option for RS+ and RS- ESA-ineligible patients with lower-risk MDS.¹

RYTELO received European Commission approval of RYTELO in March 2025 as a monotherapy for the treatment of adult patients with transfusion-dependent anemia due to very-low, low, or intermediate risk myelodysplastic syndromes (lower risk MDS or LR-MDS) without an isolated deletion 5q cytogenetic (non-del 5q) abnormality and who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy.

Geron has engaged Tanner Pharma to provide medicine to eligible patients outside of the US where imeteLstat is not yet commercially available through a Named Patient Program. Eligible patients have a serious or life-threatening condition and no suitable alternative treatments. Programs such as this support urgent medical need while maintaining regulatory control and product quality.

Please see RYTELO (imeteLstat) full Prescribing Information, including Medication Guide, available at https://pi.geron.com/products/US/pi/rytelo_pi.pdf.

Supporting Patient Access



Patient Access

The REACH4RYTELO Patient Support Program helps patients who have been prescribed RYTELO navigate access and reimbursement. Our patient affordability programs aim to close the gap for eligible patients between the cost of medication and infusions and the patient's ability to pay. Our patient assistance program provides eligible patients in need with medication free of charge. Our copay program provides eligible, commercially insured patients help with paying for the cost of RYTELO and the infusion.



Prescriber Support

We provide HCP resources to facilitate patient access to RYTELO. Our Field Reimbursement teams and resources provide information on ordering RYTELO, coverage and reimbursement, and patient support.



Payors

We engage government and commercial payors to ensure broad access to RYTELO.

¹Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myelodysplastic Syndromes V.3.2026.

© National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed April 15, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Healthier People

Advocacy & Education

We are committed to understanding the patient journey and the evolving needs of people living with lower-risk myelodysplastic syndromes (LR-MDS) and their care partners.

Through a **patient-centered approach**, we partner with patient advocacy organizations and professional societies to create resources, raise awareness about LR-MDS, and educate to empower patients to make informed healthcare decisions. We are energized by meaningful connections that help improve outcomes through delivering innovative therapies to those in need.

Our advocacy partners have an aligned dedication to advancing disease and treatment education, shared decision-making, and patient empowerment. Together, these efforts contribute to improving patient care and enhancing the overall quality of life for the LR-MDS community.

2025 Advocacy Highlights:

Launched 'Igniting Connection,' an advocacy forum uniting

30

Patient Advocacy organizations & Professional Societies serving the MDS community

Awarded

25+

Grants & Sponsorships to support education and develop resources for the MDS community

Team Geron engaged with

500+

Individuals living with LR-MDS

Engagement Highlights

Each patient's journey is unique, and we are mindful that experiences, preferences, and treatment goals are individual and require a customized approach. Mindful of the vital role that advocacy organizations play in offering tailored support, we aim to provide meaningful education and resources through convenient and trusted channels.

Our commitment is demonstrated through our community involvement and educational programs:

- Supporting Patient Advocacy educational programming such as webinars, podcasts, in-person conferences, and patient friendly resources to educate the community on disease and treatment options
- Sponsoring the MDS Foundation's Move for MDS walks and the American Society of Hematology (ASH) Foundation's Run/Walk to drive awareness of LR-MDS
- Partnering with the MDS Alliance to present RYTELO data and patient outcomes to a large advocate audience and learn about unmet needs and challenges in LR-MDS

Healthier People

Powerful Partnership: Engaging Key Stakeholders

Meeting with external stakeholders strengthens our strategies and helps inform our approach to issues. In 2025, we engaged with audiences including:

Patient Advocacy Organizations (PAGs)

- To amplify patient centricity and ensure we understand and address all aspects of the patient journey.

Professional and Medical Societies

- To exchange data, insights, and best practices while ensuring we stay current in emerging trends on clinical research and HCP education.

Government Organizations and Regulators

- To address questions related to standards and regulations, explore areas collaboration, and promote better health practices.

Pharmaceutical and Biotech Associations

- To ensure we stay apprised of key issues shaping the pharmaceutical industry and are implementing best practices.

Academic Centers and Research Institutions

- To pursue research collaborations and opportunities for data collection.

Investors and Analysts

- To understand key factors shaping the market and provide transparent reports on our goals and performance.

Nonprofit Non-governmental Organizations (NGOs)

- To improve access to medicines in underserved markets, gain insights into patient needs, and amplify disease awareness.

Healthier People

Addressing Lower-risk MDS Treatment Challenges

Lower-risk myelodysplastic syndromes (LR-MDS) is a blood cancer that often progresses to require increasingly intensified management of key symptoms such as anemia and resulting fatigue. These symptomatic LR-MDS patients frequently become red blood cell transfusion dependent, which has been shown to be associated with short- and long-term clinical consequences that reduce quality of life and shorten survival. There is a high unmet need for many LR-MDS patients, particularly those with disease characteristics that often lead to poorer prognosis.

Clinical Trials and Pipeline

We support a clinical research workforce and have frameworks for ensuring our clinical trial enrollment matches disease epidemiology. We strive to ensure patients are aware of and encouraged to participate in clinical trials

Imetelstat is being investigated in clinical trials for the treatment of hematologic malignancies, and Geron is advancing a next generation preclinical telomerase inhibitor program. View our [full pipeline](#).

- To learn about our clinical trials, [click here](#).
- To see clinical trials that are currently underway and to find out if a study is enrolling patients with your condition and in your area, please visit www.clinicaltrials.gov.
- To learn more about cancer clinical trials, please visit Cancer.gov.

Healthier People



Medical Affairs Highlights

We actively support the dissemination of medical information at scientific, medical and industry conferences by:

- Issuing posters and oral presentations
- Attending medical meetings and engaging HCPs to increase scientific understanding
- Providing grant funding to independent medical education symposia

Real World Evidence (RWE) Generation and Investigator Sponsored Research (ISR)

Geron is advancing RWE and ISR studies through targeted engagement with academic centers that reinforce the high interest in imetelstat. This harnesses the promise of RWE and ISR to compliment the registrational clinical trial data and fill in evidence gaps identified through market insights linked to clinical and commercial planning. We use RWE and outcomes methodologies to help shape our market access strategies with payers and for global market access with health technology assessment (HTA) submissions.

Geron supported more than 10 investigator-sponsored and real-world experience trials focusing on RYTELO's mechanistic studies, combinations and sequencing, earlier-line use, and new settings. Through collaborating with leading provider entities and Key Opinion Leaders, RWE trials are discovering evidence not captured in clinical trials or real-world data sets, to further reinforce efficacy and safety.

Healthier People

Relevant Policies and Procedures

Clinical Trial Research

Geron has several policies and standard operating procedures that govern the registration, execution and oversight of all Geron sponsored clinical trials.

Ethical Product Marketing, Interactions with Customers

Geron's policies are designed to ensure that all interactions with healthcare professionals and patients comply with applicable laws and regulations, as well as the principles set forth in PhRMA's Code on Interactions with Health Care Professionals. Geron is committed to ethical engagements with health care professionals, only contracting for necessary services at fair market value rates, and complying with all relevant anti-kickback and anti-bribery laws.

Interactions with Patients

Geron communicates with patients and caregivers to show support, increase disease awareness and understanding, and ensure that information is available about clinical trials and treatment options. Geron places a strong emphasis on ensuring that its interactions with patients are thoughtful, transparent, and do not interfere with the relationship between patients and their healthcare providers. Our policies are designed to ensure that all interactions with patient organizations comply with applicable laws and regulations, as well as the principles set forth in PhRMA's Principles on Interactions with Patient Organizations.

Patient and Product Quality and Safety; Counterfeit Drugs

Geron is committed to patient safety. Our policy is to comply with applicable requirements of local regulatory agencies. We have implemented serialization practices into our supply chain to identify counterfeit product and adhere to the Drug Supply Chain Security Act (DSCSA) in the U.S.

Quality Management System (QMS)

Geron's QMS is a comprehensive framework that is designed to ensure the quality, safety, and compliance of our product throughout its lifecycle. It encompasses policies, procedures and processes designed to maintain consistent product quality, from starting materials and drug substance to the final drug product. Geron conducts regular audits of our external partners to ensure compliance with regulatory requirements and continuously evaluates internal quality standards to incorporate evolving regulatory and industry best practices. Adverse events and product complaints from our patients and partners worldwide are collected, monitored, and reported through Geron's robust pharmacovigilance and quality systems. Our internal quality and pharmacovigilance teams provide trainings to employees, consultants, and external partners to ensure appropriate reporting and handling of product quality and safety information enabling timely and accurate communication with regulators, healthcare providers and patients.

Human Capital

Fostering and Maintaining a Strong, Healthy Culture

We strive to shape a culture of belonging and inclusiveness that respects co-workers, values employees' health and well-being, facilitates transparency, and fosters professional development as we carry out our mission.

We believe having a team of people with wide ranging backgrounds, experiences, perspectives, perspectives, and skillsets enhances our culture and is integral to our long-term success.

Values

Our values reflect who we are and the way our employees interact with one another, our partners, and our shareholders. They guide our decisions, relationships, ethos, and communications and play a significant role in our success.

Professional Development

We support employee growth and development in various ways, including with group workshops, individual mentoring and coaching, conference attendance, and tuition reimbursement. We also utilize a tool called Insights Discovery to understand personality preferences, improve communication, and enhance team dynamics.

Our Core Values



Pioneering Pathways

Pioneering innovative blood cancer therapies requires forging new pathways in science and in how we work. We believe positive disruption and transformation comes through continuous learning and seeking opportunities for growth.



Better Together

Our differences make us stronger. Constructive discourse and collaboration among people with diverse backgrounds, experiences, and strengths bring us new perspectives and insights that elevate our work.



Always Authentic

Our 'work hard/care hard' culture is rooted in authenticity and respect. We act with good intent and are real with each other. We are passionate about our mission, honest with our feedback, respectful of people, and encouraging of others to be their authentic selves.



Purpose-driven

At Geron, every individual in every role can meaningfully contribute to our effort to change patients' lives. We believe in the power of telomerase inhibition and are focused on bringing novel medicines to patients as quickly as possible, always acting ethically and with integrity.

Human Capital

Health and Wellness Benefits

We promote our employees' health and wellness through a range of benefits. These include reimbursement for certain wellness costs and external support from our employee assistance programs and mental wellness services, which cover therapy and/or coaching for our employees and their dependents, including high school and college-aged children.

Connectivity

We leverage our hybrid working model to be a strategic advantage. While offering the day-to-day benefit of virtual work for most employees, we also enjoy a variety of meaningful ways to connect. We strengthen our relationships with colleagues, both virtually and in person, with activities like:

- Summer connectivity event: "Summer Sound Off"
- Patient advocacy organization events
- Regular in-office meetings for some teams
- Annual offsites/team-building events

Employee Recognition

Since 2021, we have utilized a peer-centric employee recognition program to empower employees to champion our workplace culture and values and promote direct praise to peers. In addition, we have implemented a reward program that enables managers to recognize employees who have demonstrated exceptional performance.

Community Volunteering

All of our employees are eligible to receive one paid volunteer day each year.

Engagement Surveys

Each year, we survey employees to learn about their experiences at Geron and to identify ways to continue strengthening the culture.

Top feedback included:



Meaningfulness

"My job makes me feel I'm a part of something meaningful"



Supportive Managers

"My People Manager cares about my concerns"



Development

"My People Manager helps me learn and grow"

Human Capital

Recruiting

We believe that our ability to attract highly skilled and talented employees in a competitive labor market is enhanced by cultivating a workplace culture of inclusivity and belonging, providing competitive compensation and benefits programs and supporting employee career development and related growth opportunities. To that end, we continue to invest resources and energy into being an employer of choice— attracting and engaging individuals who are innovative, curious, driven, diligent, collaborative and of the highest integrity and ethics.

Geron's recruitment involves adopting a holistic approach to talent acquisition, with a focus on ethical and responsible practices. It encompasses sourcing candidates who align with our organization's values and purpose, treating candidates with respect throughout the recruitment process, promoting access to hiring opportunities, and considering the entire candidate experience. This includes creating a positive and inclusive recruitment environment, where all candidates are seen and evaluated fairly. By fostering an inclusive culture, we can attract a wide range of talent and benefit from diverse perspectives and ideas.

Recent Workplace Awards and Recognitions



Governance

Governing with Integrity and Impact

We are committed to excellence in corporate governance, risk management, and business practices. We believe our approach safeguards our accountability to the long-term interests of patients with blood cancer, our shareholders, team, and other stakeholders.

Board

Leadership

All of our current Board directors are independent, other than the CEO. Our Chair of the Board is independent and has clearly delineated duties and authority. Our Audit Committee meets regularly, including meeting with the independent directors.

Committees

- **Audit Committee:** oversees our accounting and financial reporting processes, including the audits of our financial statements by our independent accounting firm, reviews the adequacy and effectiveness of our information and cybersecurity policies, and internal controls regarding finance, accounting, financial reporting, public disclosures, and information security; meets periodically with members of management, our independent auditors, and the head of our Information Technology function to understand our policies and procedures with respect to risk assessment and risk management, including information and cybersecurity risks
- **Compensation Committee:** annually reviews each executive's demonstration of our corporate values—authenticity, accountability, excellence, integrity, and respect—in connection with annual compensation decisions; meets approximately quarterly with our Chief People Officer to review our human capital management activities
- **Nominating and Corporate Governance Committee:** identifies and evaluates qualified director candidates; advises the Board on selection of nominees for director elections and recommends Board committee assignments; reviews responsible business, corporate governance, and good corporate citizenship strategies, documents, policies, and procedures

Practices

We frequently review our practices, including:

- Our full Board and individual Board committees provide risk oversight
- Members of the Board and each Board committee annually perform anonymous self-evaluations reviewed by the Nominating and Corporate Governance Committee
- Our Board annually approves corporate budget spend
- Our Board and committees may engage outside advisors independently of management
- Stockholders can communicate with the Board in writing and deliver the communication in person or through mail

Governance



Board Composition

We prioritize having a Board with a diversity of expertise, skills, perspectives, and experiences in areas that are relevant to our business and the needs of the Board. As part of the director search process, the Nominating and Corporate Governance Committee endeavors to consider qualified candidates who meet the relevant business and search criteria and seeks candidates with diversity of personal backgrounds, perspectives, and experiences.

Compensation

Our Board maintains a performance compensation philosophy. To minimize risk and provide regular oversight, the Compensation Committee annually evaluates our compensation philosophy. Our robust compensation-setting process includes:

- Setting annual base salaries consistent with the responsibilities of our executive management team and access to market comparables to ensure that our executive management team is not motivated to take excessive risks to achieve a reasonable level of financial security
- Establishing corporate goals for our annual performance-based bonus program that are consistent with our annual operating and strategic plans and are designed to achieve a proper risk/reward balance without excessive risk taking
- Including clawback provisions in our employment agreements for each member of our executive management team
- Requiring any member of the executive management team to forfeit their entire annual performance-based bonus if determined that they engaged in any misconduct intended to affect the payment of their annual performance-based bonus, or has otherwise engaged in any act or omission that would constitute cause for termination of his or her employment, as defined by his or her employment agreement
- Granting equity compensation primarily in the form of stock options and restricted stock units subject to multi-year vesting, the value of which depends on the performance of our stock price, to encourage our executive management team to take a long-term view of our business
- Having an independent compensation consultant report directly to the Compensation Committee

Governance



Stockholder Rights and Accountability

Although directors are elected by a plurality of votes cast, we maintain a director resignation policy that requires any director nominee who receives more withhold votes than for votes in an election to submit an offer of resignation for consideration by the Nominating and Corporate Governance Committee and thereafter, the Board determines whether or not to accept the director's resignation.

Code of Business Conduct and Ethics

Our [Code of Business Conduct and Ethics \(Code\)](#) reflects the business practices and principles of behavior that support our commitment to maintaining high standards of business conduct and ethics. The code outlines guiding principles and policies related to compliance with health care laws and regulations, product quality, pharmacovigilance and regulatory compliance, privacy and information security policies, and anti-harassment and anti-discrimination policies. All our directors, employees, and members of our executive management team are required to adhere to the Code. Employees are required to report any conduct they believe in good faith to be an actual or apparent violation of the Code.

Compliance Program

With our culture of compliance and responsible and ethical conduct, we believe it is everyone's responsibility to uphold our Code. We conduct annual healthcare compliance training. Our program of awareness, training, and review is intended to facilitate compliance. We believe that training increases awareness of a wide range of ethical and legal issues in the workplace, such as conflicts of interest, bribery and corruption, insider trading, data privacy, information security, and avoiding hostile work environments. Our Legal, Human Resources, and Compliance resources oversee compliance with our Code.

Whistleblower Hotline

Geron's [Whistleblower Hotline](#) is an anonymous hotline for questions or reports regarding accounting, internal accounting controls, auditing matters, questionable financial practices or violations of our Code. Complaints received by this hotline are reviewed by the Audit Committee of our Board of Directors, Chief Financial Officer, and Legal/Compliance.

Governance



Relevant Policies

Anti-Corruption and Anti-Bribery

We have a specific internal Anti-Corruption and Anti-Bribery Policy. This topic is also addressed in our [Code](#).

Conflicts of Interest

Our Conflicts of Interest policy outlines how employees should avoid conflicts of interest that occur when their personal interests may interfere with the performance of their duties or the best interests of Geron. It is outlined in our [Code](#).

Data Privacy and Cybersecurity

Our [Privacy Policy](#) outlines our compliance with applicable data protection laws, including the European General Data Protection Regulation (GDPR) and applicable UK privacy laws. We also have multiple internal policies on these topics and address privacy in our [Code](#). Questions regarding privacy can be sent to privacy@geron.com.

Human Rights

We respect human rights, starting with setting a company culture of inclusivity and openness. Our efforts to respect the rights of people are guided by principles of the United Nations and International Labor Organization and include prohibition of child and forced labor, non-discrimination, workplace security and anti-harassment, freedom of association, data privacy, environmental health, safety, and sustainability.

Insider Trading Policy

Our [insider trading policy](#) applies to any Geron employee, director, or designated consultant. It prohibits short sales, transactions in put or call options, hedging transactions, pledging our common stock as collateral for a loan, or other inherently speculative transactions in our stock or engaging in margin activities.

Government Interactions

We are committed to engaging with government-related entities in an honest, ethical, and equitable manner and maintain guidelines for employees when interacting with government entities. We also aim to collaborate with all reasonable requests from government regulatory and enforcement agencies and have implemented procedures. Additional details can be found in our [Code](#).

Governance

Supplier Conduct

Our Supplier standards and Quality System assurances are outlined in our [Code](#). Geron maintains:

- Control procedures to ensure that our products and manufacturing processes comply to applicable regulations
- A supplier quality assurance program to ensure that purchased products and services meet defined specifications and regulatory requirements
- Procedures to identify, isolate, and control nonconforming products, investigate root causes of nonconformance, and implement corrective and preventative action to reduce recurrence
- A quality-managed process for the qualification and onboarding of Good Practice (GxP) suppliers

Industry Memberships

The logo for MASSBIO, featuring the word "MASSBIO" in a bold, teal, sans-serif font.The logo for the Biotechnology Innovation Organization, featuring a stylized "Bio" in white on a teal background, followed by the text "Biotechnology Innovation Organization" in a teal, sans-serif font.

Environment



A Note on the Environment

We seek to conduct our business in an environmentally sound manner. We do not own or operate manufacturing facilities or own lab or office spaces. We also outsource all our clinical trials to clinical research organizations (CROs). We are mindful of our impact on the environment throughout our business operations and dedicated to compliance with regulations.

Practices

Environmental Compliance

As outlined in our Code, we adhere to environmental laws. We are committed to minimizing or eliminating (if possible) the use of any substance or material that may cause environmental damage, reducing waste generation, and disposing of all waste through safe and responsible methods, employing safe technologies and operating procedures, and preparing for accident and emergency responses.

Manufacturing

We rely on third-party contract manufacturers to produce and supply RYTELO (imetelstat) for clinical and commercial use. We do not have direct control over third-party personnel or operations. We conduct regular audits of our third-party contract manufacturers to assess compliance with applicable GXP requirements.

Offices

Our San Francisco Bay Area and Northern New Jersey offices are in a multi-tenant, energy efficient, ENERGY STAR-certified building. Our office suites are environmentally friendly in their use of electricity, water, and power.

Commuter and Remote Work Benefits

We offer a flexible spending account (FSA) for commuter spending. This enables employees to use pre-tax dollars to pay for public transit costs when traveling from home into a Geron corporate office. We provide equipment for home office use and a monthly stipend to cover work-from-home expenses.

About Geron

Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. To learn more, visit www.geron.com or follow us on [LinkedIn](#).

Contacts

For questions about Geron’s corporate governance, Code of Conduct and policies, please email secretary@geron.com. For investor questions, please email investor@geron.com.

For media questions, please email media@geron.com.

Forward-Looking Statements

Except for the historical information contained herein, this report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended (PSLRA), including, but not limited to: (a) our corporate mission, goals and efforts to develop, commercialize and make available to eligible patients RYTELO® (imetelstat) and to make a positive impact through how we conduct our business, our compassion for our patients and our service to the community; (b) statements relating to the therapeutic and commercial potential of RYTELO® (imetelstat) and the continued development and commercialization of RYTELO, including our plans to commercialize and provide access to RYTELO outside of the United States; (c) the aims, objectives and intent of our patient access programs, including the REACH4RYTELO patient support program, and prescriber support programs; (d) the goals, considerations, expectations and objectives of our Healthier People, Human Capital, Governance, and Environment strategies, initiatives policies and practices, including any goals, targets, ambitions, commitments, or aspirations relating to environmental, social and governance (ESG) matters; and (e) other statements that are not historical facts. These statements involve risks, uncertainties and other factors that can cause actual results to differ materially from those expressed or implied by such forward-looking statements. These risks, uncertainties, and other factors include, without limitation, those risks and uncertainties described in our periodic reports filed with the Securities and Exchange Commission (SEC) under the heading “Risk Factors,” including our Annual Report on Form 10-K for the year ended December 31, 2025, in our subsequent reports on Form 10-Q, and in other filings made with the SEC. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made and the facts and assumptions underlying the forward-looking statements may change. Except as required by law, we disclaim any obligation to update these forward-looking statements to reflect new information, future events, changed circumstances or otherwise.

